Complex I Deficiency in Parkinson’s Disease and MPTP-Induced Experimental Parkinsonism

  • Yoshikuni Mizuno
  • Keiji Suzuki
Part of the Advances in Behavioral Biology book series (ABBI, volume 38A)


It has been considered that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced parkinsonism is the best model available at present of Parkinson’s disease. Elucidation of the mechanism of the neuronal degeneration in this model will contribute to the studies on the pathogenesis of Parkinson’s disease. In this communication, we will present our data on the mechanism of the neuronal degeneration in MPTP-induced experimental parkinsonism and a preliminary observation on Parkinson’s disease.


Neuronal Degeneration Mitochondrial Complex Hydrophobic Fraction Jichi Medical School Postmortem Period 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J. M. Langston, I. Irwin, E. B. Langston and L. S. Forno, 1-Methyl4-phenylpyridinium ion (MPP+): Identification of a metabolite of MPTP, A toxin selective to the substantia nigra, Neurosci. Lett., 48: 87 (1984).PubMedCrossRefGoogle Scholar
  2. 2.
    K. Chiba, A. J. Trevor and N. Castagnoli, Jr., Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes, Biochem. Biophys. Res. Commun., 128: 1229 (1984).Google Scholar
  3. 3.
    K. Ozawa, L. Seta, H. Takeda, K. Ando, H. Handa and C. Araki, On the isolation of mitochondria with high respiratory control from rat brain, J. Biochem., 59: 501 (1966).PubMedGoogle Scholar
  4. 4.
    Y. Mizuno, N. Sone and T. Saitoh, Dopaminergic neurotoxins, MPTP and MPP, inhibit mitochondrial NADH-ubiquinone oxidoreductase activity, Proc. Japan Acad., Ser. B, 62: 261 (1986).CrossRefGoogle Scholar
  5. 5.
    Y. Mizuno, N. Sone and T. Saitoh, Effects of 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain, J. Neurochem., 48: 1787 (1987).PubMedCrossRefGoogle Scholar
  6. 6.
    I. Irwin, and J. W. Langston, Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity? Life Sci., 36: 207 (1985).PubMedCrossRefGoogle Scholar
  7. 7.
    R. R. Ramsay and T. P. Singer, Energy-dependent uptake of N-methyl4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine, by mitochondria, J. Biol. Chem., 261: 7585 (1986).PubMedGoogle Scholar
  8. 8.
    Y. Mizuno, T. Saitoh and N. Sone, Inhibition of mitochondrial NADHubiquinone oxidoreductase activity by 1-methyl-4-phenyl-pyridinium ion, Biochem. Biophys. Res. Commun., 143: 294 (1987).PubMedCrossRefGoogle Scholar
  9. 9.
    Y. Mizuno, N. Sone, K. Suzuki and T. Saitoh, Studies on toxicity of 1-methyl-4-phenylpyridinium ion against mitochondria of mouse brain, J. Neurol. Sci., 86: 97 (1988).PubMedCrossRefGoogle Scholar
  10. 10.
    Y. Mizuno, T. Saitoh and N. Sone, Inhibition of mitochondrial alphaketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion, Biochem. Biophys. Res. Commun., 143: 971 (1987).PubMedCrossRefGoogle Scholar
  11. 11.
    J. C. K. Lai and A. J. L. Cooper, Brain alpha-ketoglutarate dehydrogenase complex: Kinetic properties, regional distribution, and effects of inhibitors, J. Neurochem., 47: 1376 (1986).PubMedCrossRefGoogle Scholar
  12. 12.
    Y. Mizuno, K. Suzuki, N. Sone and T. Saitoh, Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain in vivo, Neurosci. Lett., 91: 349 (1988).PubMedCrossRefGoogle Scholar
  13. 13.
    K. Chiba, A. J. Trevor and N. Castagnoli, Jr., Metabolism of the neuro-toxic tertiary amine, MPTP, by brain monoamine oxidase, Biochem. Biophys. Res. Commun., 120: 574 (1984).PubMedCrossRefGoogle Scholar
  14. 14.
    R. R. Ramsay, K. A. McKeown, E. A. Johnson, R. G. Booth and T. P. Singer, Inhibition of NADH oxidation by pyridine derivatives, Biochem. Biophys. Res. Commun., 146: 53 (1987).PubMedCrossRefGoogle Scholar
  15. 15.
    Y. Mizuno, S. Ohta, M. Tanaka, S. Takamiya, K. Suzuki, H. Oya, T. Ozawa and Y. Kagawa, Deficiencies in Complex I subunits of the respiratory chain in Parkinson’s disease, Biochem. Biophys. Res. Commun., (in press) (1989).Google Scholar
  16. 16.
    A. H. V. Schapira, J. M. Cooper, D. Dexter, P. Jenner, J. B. Clark and C. D. Marsden, Mitochondrial Complex I deficiency in Parkinson’s disease, Lancet, 1: 1269 (1989).PubMedCrossRefGoogle Scholar
  17. 17.
    L. A. Bindoff, M. Birch-Machin, N. E. F. Cartlidge, W. D. Parker, Jr. and D. M. Turnbull, Mitochondrial function in Parkinson’s disease, Lancet, 2: 49 (1989).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Yoshikuni Mizuno
    • 1
  • Keiji Suzuki
    • 2
  1. 1.Department of NeurologyJuntendo University School of MedicineTokyoJapan
  2. 2.Department of NeurologyJichi Medical SchoolTochigiJapan

Personalised recommendations